Immunology Clinical Trials Update: Week 27, 2026

Published July 3, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis

This Phase 3 trial is testing a new injection called Stapokibart for adolescents suffering from seasonal allergic rhinitis, which causes symptoms like nasal congestion and sneezing. If the treatment proves safe and effective, it could become a new option to help young patients manage these uncomfortable allergy symptoms more easily. The study is recruiting participants in China and will assess results after two weeks of treatment.

TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children

This Phase 2 trial is exploring a new type of stem cell transplant for children with primary immune deficiency disorders and inherited metabolic conditions. The approach uses specially processed donor cells from family members to potentially make the transplant safer and more effective. Currently recruiting in the United States, this study could lead to improved treatment options for children facing these serious immune system challenges.

Safety and Immunogenicity Study of Tdap Vaccinations for Plasma Donors

This completed Phase 2 study looked at how safe and effective repeated Tdap vaccinations are for healthy plasma donors. It tested whether multiple doses within a year produce a good immune response without causing problems. The results, gathered from 107 participants in the United States, may influence future vaccination schedules for people who regularly donate plasma.

Study of PlasmaCap IG in Adults and Children With PIDD

This Phase 3 trial evaluated PlasmaCap IG, an intravenous treatment designed to support the immune system in adults and children with primary immune deficiency diseases. By boosting immune function, this treatment aims to reduce the risk of infections for people with weakened immune systems. The study has finished and included multiple sites across the US and Canada, offering valuable information about this potential therapy.

Model Early Immunologic Stages of Pediatric Hematological Pre-lupus

This study is investigating immune system markers in children with immune thrombocytopenic purpura and lupus to better understand the early stages of these conditions. By identifying children at risk of developing lupus, the research may help improve how doctors monitor and prevent disease progression. The study is currently recruiting in France and involves collecting blood samples over several months.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.